The arthritis pain management market is projected to grow at a considerable CAGR of 5.2% during the forecast period (2019-2025). The rising incidence of arthritis disorder due to a sedentary lifestyle is a major factor driving the growth of the global arthritis pain management industry. With the advancement in healthcare facilities across the globe, the life expectancy of people has been increased across the globe. According to the Centre for Disease Control and Prevention (CDC), an estimated 78 million US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. According to the World Health Organization (WHO), the number of people aged 65 years or older is anticipated to increase from 605 million to 2 billion by 2050.

The geriatric population is more susceptible to this kind of disorder, therefore the increasing number of geriatric populations across the globe may also demand treatment of this disorder, hence promoting the market growth of the arthritis pain management market.The upcoming therapy such as the Anti-nerve growth factor is anticipated to create opportunities for the growth of the global arthritis pain management market. This is due to the fact that this therapy offers faster relief in chronic pain, and thus improves the movement of joint among the patients.

Segmental Outlook  

The arthritis pain management market is segmented on the basis of drug type, and end-user. Based on the drug type market is segmented into anti-inflammatory biologics, disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and others. NSAIDs drugs include Celecoxib (Celebrex), Piroxicam (Feldene), Nabumetone (Relafen), prescription-strength ibuprofen and naproxen. As this drug not only provides relief to the pain but also reduces the swelling of the knees these drugs are anticipated to hold considerable market share during the forecast period.Based on end-user the market is segmented into hospitals, ambulatory surgical centers(ASCs), and others.

Hospitals will be considerable segment by End-User

Hospitals are anticipated to hold considerable market share based on end-user. This is due to many inpatient and outpatient visits to hospitals. Further, a significant requirement of a large volume of drugs along with their respective devices to fulfill the demand of the large patient pool is also augmenting the growth of this market segment.

Global Arthritis Pain Management Market Share by End-User, 2018 (%)

Regional Outlook 

The global arthritis pain management market is further segmented on the basis of geography including North America, Europe, Asia-Pacific and Rest of the World. North America is anticipated to hold a major market share during the forecast period. The presence of key market players of the arthritis pain management market including Johnson & Johnson Services, Inc., Pfizer, Inc., and Amgen Inc. in the region have been a major contributor to the high market share. The proper medical reimbursement policy, high disposable income, and rising incidences of arthritis with improvements and advancements in healthcare facilities in the region further promote the growth of the regional market. North America is followed by Europe and the Asia-Pacific is projected to be the fastest-growing market during the forecasted period.

Global Arthritis Pain Management Market Growth, by Region 2019-2025

Asia-Pacific will augment with the significant growth rate in the arthritis pain management market 

The emerging countries of Asia-Pacific including China and India, are projected to witness a significant growth rate over the forecast period. The presence of a large targeted patient pool that requires treatment for their arthritis along with cohesive government initiatives in the form of funding is anticipated to fuel the market growth in the arthritis pain management market.The increasing number of trained joint replacement surgeons along with increasing sedentary lifestyle, rising healthcare expenditure, the rising medical tourism and improved healthcare infrastructure of the Asia-Pacific region are the other factor that is driving the growth of arthritis pain management market in the region.

Market Players Outlook

The key players of the arthritis pain management market include Johnson & Johnson Services Inc., f. Hoffman La Roche, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Abbvie, Inc., Allergen PLC, Bayer AG, Amgen Inc., and so on. These key market players are actively adopting strategic growth activities including mergers and acquisitions, partnerships and collaboration among others to enhance their market presence. The FDA approval for new product launches is the core strength of these key market players of the arthritis management market to stay competitive in the market. For instance, in August 2019, Abbvie received approval for upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor. Rinvoq 15 mg is used for the treatment of adults with moderate to severely active rheumatoid arthritis (RA). This drug is given to the patient who had an inadequate response or intolerance to methotrexate (MTX-IR) drug.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global arthritis pain management market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.